Accès ouvert

Prevalence of amyloid blood clots in COVID-19 plasma

Article scientifique 2020 Anglais

Résumé

Abstract The rapid detection of COVID-19 uses genotypic testing for the presence of SARS-Cov-2 virus in nasopharyngeal swabs, but it can have a poor sensitivity. A rapid, host-based physiological test that indicated whether the individual was infected or not would be highly desirable. Coagulaopathies are a common accompaniment to COVID-19, especially micro-clots within the lungs. We show here that microclots can be detected in the native plasma of COVID-19 patient, and in particular that such clots are amyloid in nature as judged by a standard fluorogenic stain. This provides a rapid and convenient test (P<0.0001), and suggests that the early detection and prevention of such clotting could have an important role in therapy.

Citer ce document

Pretorius, E., Venter, C., Laubscher, G., Lourens, P., Steenkamp, J., Kell, D. (2020). Prevalence of amyloid blood clots in COVID-19 plasma. https://doi.org/10.1101/2020.07.28.20163543

Accès au document

Ce lien n'est plus accessible actuellement. Contactez l'institution d'origine.

Auteur(s)

Etheresia Pretorius Chantelle Venter Gert Jacobus Laubscher Petrus Johannes Lourens Janami Steenkamp Douglas B. Kell

Statistiques

Consultations : 1

Téléchargements : 0